Analysts Expect 10% Gains Ahead For The Holdings of DIVB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Price Insights: The iShares Core Dividend ETF (DIVB) has an implied analyst target price of $53.27, indicating a potential upside of 10.47% from its current trading price of $48.22. Notable underlying holdings with significant upside include DENTSPLY SIRONA Inc, Victory Capital Holdings Inc, and Cohen & Steers Inc.
Market Sentiment and Analyst Justifications: There are questions regarding whether analysts' target prices are justified or overly optimistic, as high targets may reflect future optimism but could also lead to downgrades if they do not align with recent market developments.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 13.04 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 13.000
Low
12.00
Averages
13.04
High
17.00
Current: 13.000
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
